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Purinergic signaling is involved in a variety of physiological states. P2 receptors are
mainly activated by adenosine triphosphate (ATP). Activation of specific P2Y receptor
subtypes might influence progression of kidney disease. To investigate the in vivo effect
of a particular P2 receptor subtype on chronic kidney disease progression, subtotal
nephrectomy was performed on wild type (WT) and P2Y2 receptor knockout (KO) mice.
During the observational period of 56 ± 2 days, survival of KO mice was inferior compared
to WT mice after SNX. Subtotal nephrectomy reduced creatinine clearance in both groups
of mice, but the decrease was significantly more pronounced in KO compared to WT mice
(53.9 ± 7.7 vs. 84.3 ± 8.7μl/min at day 56). The KO mice also sustained a greater increase
in systolic blood pressure after SNX compared to WT mice (177 ± 2 vs. 156 ± 7mmHg)
and a 2.5-fold increase in albuminuria compared to WT. In addition, WT kidneys showed a
significant increase in remnant kidney mass 56 days after SNX, but significant attenuation
of hypertrophy in KO mice was observed. In line with the observed hypertrophy in
WT SNX mice, a significant dose-dependent increase in DNA synthesis, a marker of
proliferation, was present in cultured WT glomerular epithelial cells upon ATP stimulation.
Markers for tissue damage (TGF-β1, PAI-1) and proinflammatory target genes (MCP1) were
significantly upregulated in KO mice after SNX compared to WT SNX mice. In summary,
deletion of the P2Y2 receptor leads to greater renal injury after SNX compared to WTmice.
Higher systolic blood pressure and inability of compensatory hypertrophy in KO mice are
likely causes for the accelerated progression of chronic kidney disease.
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INTRODUCTION
Nucleotides, predominantly adenosine triphosphate (ATP) and
uridine triphosphate (UTP), are the ligands for P2 receptors.
Intracellular ATP serves as the main source of energy and is cru-
cial for almost all cell functions. Released from either neurons
as neurotransmitters or in a paracrine fashion from a vari-
ety of cells and tissues, these nucleotides activate P2 receptors
to trigger intracellular pathways (Ralevic and Burnstock, 1991;
Burnstock, 1995; Oberhauser et al., 1999; Vonend et al., 2002;
Ralevic and Burnstock, 2003; Vonend et al., 2003; Burnstock,
2006).
In almost every organsystem expression of several P2 recep-
tor subtypes can be found (Turner et al., 2003; Burnstock and
Knight, 2004). Activation of P2 receptors plays a role in transep-
ithelial transport, proliferation, migration, platelet aggregation
and has a potential influence on cardiovascular diseases. There are
Abbreviations: ATP, adenosine triphosphate; BP, blood pressure; DNA, deoxyri-
bonucleic acid; FCS, fetal calf serum; h, hour; KO, knock out; NaOH, sodium
hydroxide; NS, non-significant; PBS, phosphate buffered saline; PCR, polymerase
chain reaction; SNX, subtotal nephrectomy; UTP, uridine triphosphate; WT, wild
type.
ligand-gated ion channel P2X receptors (P2X1−7) and G-protein
coupled P2Y receptors (P2Y1,2,4,6,11−14) (Abbracchio et al., 2006;
Burnstock, 2012). In the kidney in particular, the expression of
multiple P2 receptors subtypes can be observed (Bailey et al.,
2000; Vonend et al., 2003, 2005).
P2 receptors play a pivotal role within the sympathetic ner-
vous system (Vonend et al., 2005; Gourine et al., 2009). As ATP
serves as a co-transmitter from sympathetic nerve endings, acti-
vation of these P2 receptors occurs in sympathetic overactivity.
It is well-known that patients with chronic kidney disease have
an increased sympathetic activity (Rump et al., 2000; Vonend
et al., 2002). In addition to ATP release from sympathetic nerve
endings, endothelial dysfunction and increased shear stress con-
tribute to a higher extracellular abundance of ATP, released from
the endothelium in chronic kidney disease (Wan et al., 2008;
Yamamoto et al., 2011).
There is evidence that P2Y receptor subtypes are important
for maintaining renal function. In particular the P2Y2 receptor is
involved in glomerular cell proliferation and modulation of renal
tubule function including natriuresis (Harada et al., 2000; Vonend
et al., 2002; O’Mullane et al., 2009; Booth et al., 2012).
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Due to the role of P2Y2 receptors in vascular and tubule
function, inflammation and renal cell proliferation, we hypoth-
esize that activation of P2Y2 receptors plays an important role
in the pathophysiology and the progression of chronic kidney
disease.
The model of subtotal nephrectomy (SNX) is characterized by
increased blood pressure and sympathetic overactivity (Potthoff
et al., 2008; Hoch et al., 2011). In this study, for the first time,
using this model in P2Y2 receptor knockout mice (P2Y2-R KO),
we assessed the effects of P2Y2 receptor on the progression of
chronic kidney disease.
METHODS
ANIMAL CARE
The P2Y2-R KO mouse was generously provided by Dr B. H.
Koller (University of North Carolina, Chapel Hill, USA). Mice
were generated by homologous recombination in embryonic stem
cell lines. Northern blot RNA analysis from kidney lysates con-
firmed the complete loss of P2Y2-R expression in these mice
(Homolya et al., 1999). The mice were originally on a B6D2
genetic background and back crossed with a SV129 mouse strain
for 10 generations before starting the study. Mice homozygous for
P2Y2-R KOwere used in this study. Genotyping was performed in
each individual mouse confirming the presence of the disrupted
P2Y2-R gene (Homolya et al., 1999). Wild type (WT) littermates
were used as controls. At the date of surgery, all mice were 62 ± 3
days old and weighed 21–26 g. Only male mice were used in this
study. The investigations and surgery were performed in accor-
dance with institutional guidelines. The animals were housed in
type III Makrolon polycarbonate cages at 45% humidity, 20–
22◦C temperature and a 12 h day-night-cycle with free access to
water and food. Standard food was Altromin (Altromin 1314: 20%
protein, 0.4% NaCl, Lage/Lippe, Germany).
SUBTOTAL NEPHRECTOMY AND SHAM SURGERY
Sham surgery or subtotal nephrectomy (SNX) was performed at
62± 3 days of age. WTmice and P2Y2-R KOmice were randomly
allocated to either sham surgery or SNX. A Kaplan-Meier survival
curve was generated from the survival data in the sham-surgery
and SNX groups.
The mice were anesthetized with ketamin and xylazine by
intraperitoneal injection (0.168mg/g and 8mg/g bodyweight,
respectively). Subtotal nephrectomy was performed as previ-
ously described (Hoch et al., 2011). In brief, both kidneys were
exposed by dorsal incision. The right kidney was removed com-
pletely. Two-thirds of the functional tissue from the left kidney
was removed by ligation of the upper and lower renal poles
leading to a subtotal reduction of functional renal tissue. Sham
surgery was performed only by skin and abdominal muscle
incisions.
PREPARATION OF URINARY, SERUM AND TISSUE SAMPLES
The mice were sacrificed 56 ± 2 days after surgery. Blood sam-
ples were gathered by retro orbital vein puncture on day 28 ± 2
and on the day of sacrifice. Serum samples were obtained from
centrifuged blood samples. Twenty-four hour-urine was collected
on day 0, 28 ± 2 and on the day of sacrifice using metabolic
cages (Techniplast, Italy) for urinary albumin, creatinine and urea
measurement.
On day 56 ± 2, mice were sacrificed, all organs were perfused
with ice-cold PBS from the left ventricle and SNX-kidneys and
sham-surgery kidneys were removed and embedded in paraffin.
Tissue samples for RNA expression analysis were removed from
the kidneys prior paraffin embedding.
SYSTOLIC BLOOD PRESSURE MEASUREMENT
Systolic blood pressure (BP) was measured non-invasively by tail-
cuff sphygmomanometer using a BP-98A device (Softron, Japan).
Mice were trained for 4 days prior to evaluation of BP. BP was
measured on day 0, 28 ± 2 and 56 ± 2 prior to sacrifice.
KIDNEY HYPERTROPHY
Kidney weight was evaluated on the day of surgery (SNX groups)
and at the end of study. The remnant kidney weight directly after
SNX was estimated by calculating the kidney weight of right kid-
ney minus the weight of the removed tissue from the left kidney.
Change in kidney weight from the day of surgery (SNX) until
sacrifice was regarded as an index of kidney hypertrophy.
QUANTIFICATION OF SERUM AND URINE ALBUMIN AND UREA
Measurement of creatinine levels in serum and urine was
performed using an enzymatic standard test supplied by
Labor&Technik, Germany. The analysis was performed following
the manufacturer’s protocol. Serum and urinary urea and serum
albumin were measured using standard tests supplied by Randox,
Germany. The methods were followed according to the manu-
facturer’s protocol. Urinary albumin levels were measured using
the AlbuwellM Kit (Exocell, USA). Urine albumin-to-creatinine
ratio (UACR) was calculated for all urine samples (24-h urine
collection samples using metabolic cages). Creatinine-clearance
was calculated from urine volume, urinary- and serum-creatinine
values.
PROLIFERATION ASSAY
[3H]-thymidine assay was used to estimate proliferative activity
in cells (Vonend et al., 2003). WT human glomerular epithelial
cells were obtained from Cambrex Corporation, USA. For prolif-
eration assays, cell passages ranging from 5 to 12 were used. Cells
were housed at 37◦C and 5% CO2. Cells were distributed on a 96-
well-plate (150.000 cells/well) and grown for 3 days in cell culture
medium containing 5% fetal calf serum until 70–80% confluence.
At day 3, cells were starved for 24 h by reducing fetal calf serum
content to 0.5%. ATP was added to resting cells (4 wells for each
concentration) for 24 h (0–100μM).
The cells were incubated with [3H]-thymidine (1μCi/ml) dur-
ing the last 6 h. Cells were washed three times with phosphate
buffered saline, twice with ice-cold 10% trichloroacetic acid, and
the fixed cellular material was solubilized in 1ml 0.5m NaOH
for 2 h and mixed with 4ml scintillation fluid (Ultima-Gold,
Canberra Packard, Frankfurt, Germany) to measure the amount
of radioactivity. Data are expressed as the mean ratio of radioac-
tivity present in the 4 wells with identical concentration divided
by control (0μMATP) values (% of control).
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RNA EXTRACTION AND REVERSE TRANSCRIPTION POLYMERASE
CHAIN REACTION
WT human glomerular epithelial cells were homoge-
nized and total RNA was isolated with Trizol-Reagent
(Invitrogen, Germany). Following DNA digestion (Rnase
free DNase/Invitrogen), mRNA was isolated from total RNA
with the PolyATract mRNA isolation system (Promega). cDNA
was synthesized according to suppliers’ protocol using oligo-dt
primer and the reverse transcriptase superscript (Invitrogen).
The amplification was performed with specific primers for
P2Y1,2,4,6,11 receptor subtypes with 10% of the first strand
cDNA and 1.5 units of Platinum Taq-Polymerase (Invitrogen)
in a volume of 50μl. After 5min at 95◦C followed by 35 cycles
consisting of 1min at 95◦C, 1min at 52–58◦C, 1min at 72◦C and
for termination 8min at 72◦C, 10μl of the reaction products
were analyzed on a 1.5% agarose gel containing ethidium
bromide.
Quantitative real time PCR (qPCR)
SNX kidney samples were used to analyze relative expression lev-
els for transforming growth factor beta 1 (TGF-β1), plasminogen
activator inhibitor 1 (PAI-1), nuclear factor kappa-light-chain-
enhancer of activated B-cells (NFκB), monocyte chemoattractant
protein 1 (MCP1), cyclooxygenase 1 (COX1) and prostaglandin E
synthase 1 (PGES1).
After homogenization of tissue with a Tissue Ruptor (Qiagen,
Germany), total RNA was isolated using a RNA Micro Kit
(Qiagen, Germany) according to the manufacturer’s instructions.
Quantitative real time PCR was performed with an ABI PRISM
7300 (Applied Biosystem, Germany) and the SYBR Green master
mix (Qiagen, Germany). The PCR reaction was performed in a
total volume of 20μl with 1μl cDNA corresponding to 50 ng
RNA as template.
The two-step PCR conditions were 2min at 50◦C, 15min
at 95◦C, followed by 40 cycles (denaturation at 94◦C for 15 s;
annealing at 55◦C for 30 s and extension at 72◦C for 34 s).
Experiments were performed in triplicate. 18S ribosomal RNA
was chosen as the endogenous control (housekeeping gene). The
levels of targeted genes were normalized to 18S rRNA expression
and analyzed by REST 2008V2.0.7 software.
The following Taqman assays were used: 18S (Mm039
28990_g1), PAI-1 (Mm00435860_m1), TGF-β1 (Mm011788
20_m1), NFκB (Mm01297400_m1), MCP1 (Mm00441242_m1),
COX1 (Mm0047214_m1), PGES1 (Mm00452105_m1).
Statistical analysis
All data are expressed as means ± standard error of mean (SEM).
n applies to the number of mice/tissue samples used in each
group. Datasets were analyzed using SPSS 19.0 software. Multiple
comparison of more than two groups was performed by One-Way
ANOVA followed by Bonferroni’s multiple comparison post-hoc
test, where applicable. Values of p < 0.05 were considered as sig-
nificant. If applicable, a higher level of statistical significance is
stated (p < 0.01, p < 0.001).
qPCR data was statistically analyzed using REST 2008V2.0.7
software.
Comparison of survival was calculated using the logrank test
(Mantel-Cox test).
RESULTS
SURVIVAL
Renal function in the model of subtotal nephrectomy is the major
contributing factor determining animal survival. To evaluate a
general role of P2Y2 receptor in the progression of chronic kid-
ney disease, we registered the survival of sham surgery and SNX
mice.
Observational period for all mice was 56 ± 2 days after
surgery. Overall survival was 100% in both sham surgery groups
(Figure 1). During the observation period, 1 out of 9 WT mice
died after SNX compared to 7 out of 19 in the P2Y2-R KO group
(survival rate WT vs. P2Y2-R KO: 88.9 vs. 63.1%) (Figure 1).
Comparing the survival with the WT sham surgery group, sur-
vival was not significantly different inWTmice (survival rate 88.9
vs. 100%, p =NS). However, survival was significantly reduced in
P2Y2-R KO mice which underwent SNX compared to KO sham
surgery mice (survival rate 63.1 vs. 100%, p < 0.01, X2 = 6.658,
df = 1).
SYSTOLIC BLOOD PRESSURE
Increase in blood pressure occurs in chronic kidney disease. It cor-
relates well with the stage of chronic kidney disease. A high blood
pressure also contributes to the progression of kidney disease.
Systolic blood pressure was measured at three different time
points (day 0, 28 ± 2, 56 ± 2) using an automated tail-cuff sphyg-
momanometer. At baseline before surgery (day 0), all four groups
showed no difference in systolic blood pressure. Neither sham
surgery groups showed a rise in systolic blood pressure during the
observation period. In contrast, the SNX groups had a significant
elevation of systolic blood pressure (day 28 and 56). In addi-
tion, systolic blood pressure was significantly higher in P2Y2-R
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FIGURE 1 | Kaplan-Meyer-survival curve of all groups: sham surgery
groups showed 100% survival after 56 ± 2 days. In the SNX surgery
groups, more WT mice survived during the observation period than P2Y2-R
KO mice (88.9 vs. 63.1%). Comparing this data to the sham surgery groups
shows that subtotal nephrectomized P2Y2-R KO mice had a significantly
reduced survival (∗∗p < 0.01) whereas subtotal nephrectomized WT mice
showed no significantly reduced survival compared to sham surgery WT
mice (p = NS).
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FIGURE 2 | Systolic blood pressure on day 0 (before surgery), day
28 and day 56 for each group: Sham surgery groups did not show
any significant change in systolic blood pressure. SNX groups
showed a significant rise in systolic blood pressure on day 28 and 56
compared to day 0 (∗p < 0.05). At day 56, systolic blood pressure was
significantly higher in P2Y2-R KO SNX compared to WT SNX mice
(#p < 0.05) (mean ± SEM).
KO mice after SNX compared to WT SNX mice (day 56, WT vs.
P2Y2-R KO: 156 ± 7 vs. 177 ± 2mmHg) (Figure 2).
RENAL FUNCTION
In order to evaluate renal function, measurement of renal reten-
tion parameters and endogenous creatinine clearance was per-
formed in all groups.
During the observation period (day 28± 2, 56± 2) there was a
significant increase in serum urea in both SNX groups compared
to baseline (day 0). There was no significant change of serum urea
in sham surgery groups (Figure 3). At day 56± 2, serum urea was
3.6-fold higher in WT SNX compared to WT sham surgery mice
and 4.4-fold higher in P2Y2-R KO SNX compared to KO sham
surgery mice. Accordingly, serum urea was significantly higher in
P2Y2-R KO SNX mice compared to WT SNX mice. This is in
line with the observed creatinine clearance at day 56: creatinine
clearance was significantly higher in WT SNX mice compared to
P2Y2-R KO SNX mice.
All assessed physiological parameters are summarized in
Table 1.
ALBUMINURIA
Mice that underwent subtotal nephrectomy are characterized by
the progression of chronic kidney disease. The histologic equiva-
lent in tissue injury is the onset and progression of glomeruloscle-
rosis and is accompanied by albuminuria.
Albuminuria, estimated by UACR, was almost absent in sham
surgery groups at all time points. In contrast, compared to base-
line, there was a significant rise in albuminuria in the SNX groups
(Figure 4). In addition, the rise in UACR was more pronounced
in P2Y2-R KO SNXmice. After 56 days, the UACR was more than
2.5-fold higher in KO SNX compared to WT SNX mice (Table 1,
Figure 4).
FIGURE 3 | Serum urea on day 0 (before surgery), day 28 and day 56 for
each group: sham surgery groups did not show any significant change
in serum urea levels. SNX groups showed a significant rise in serum urea
levels on day 28 and 56 compared to day 0 (∗p < 0.05). At day 28 and 56,
serum urea levels were significantly higher in P2Y2-R KO SNX compared to
WT SNX mice (#p < 0.05) (mean ± SEM).
Marked differences in glomerulosclerosis between P2Y2-R KO
SNX and WT SNX mice could not be detected (data not shown).
GENE EXPRESSION
Kidney cortex tissue from SNX mice at day 56 was assessed
for the expression of specific genes which are associated with
inflammatory response and which are related to the func-
tion of P2Y2-receptor in the immune system. In addition,
gene expression was assessed for genes related to kidney
injury.
In qPCR analysis, wecompared the expression level of specific
target genes in P2Y2-R KO SNX mice to the expression in WT
SNX mice. qPCR results were normalized to 18S ribosomal RNA
expression. Comparison revealed a significant increase in expres-
sion ratio for TGF-β1, PAI-1 and MCP1 in P2Y2-R KO SNX mice
(Table 2, Figure 5).
HYPERTROPHY OF KIDNEY TISSUE
Loss of kidney tissue results in the hypertrophy of the healthy
remnant kidney, partially compensating for the loss of functional
tissue. Since the P2Y2-receptor is involved in cell proliferation, we
assessed the increase in kidney weight.
In SNX mice, at day 0, total kidney weight (two kidneys) was
reduced to a similar extent in WT and KO mice (WT: −69.3 ±
1.35%; P2Y2-R KO: −68.7 ± 1.1%).
At day 56, SNX kidney weight was measured and compared
to the estimated weight at day 0. Comparison of the SNX groups
showed a significant difference at day 56 (Figure 6A). Remnant
kidney weight in WT SNXmice increased significantly during the
observational period (day 56, 150 ± 6% compared to day 0, p <
0.05). In contrast, SNX in P2Y2-R KO mice led to a minor, non-
significant increase in remnant kidney weight (day 56, 113 ± 6%
compared to day 0, p = NS).
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Table 1 | Serum and urine parameters from all groups after 56 ± 2 days.
Parameter Units (SI) WT-SNX P2Y2–R KO-SNX WT-sham P2Y2-R KO-sham
Serum creatinine μmol/l 19.5 ± 3.5 24.8 ± 2.7 9.7 ± 0.7 4.4 ± 0.4
Serum urea* mmol/l 27.1 ± 2.1 47.4 ± 5.2 7.5 ± 0.1 10.8 ± 0.8
Urine volume (24 h) ml 1.8 ± 0.2 2.6 ± 0.4 0.4 ± 0.1 0.2 ± 0.1
Creatinine clearance* μl/min 84 ± 9 54 ± 8 114 ± 14 112 ± 29
Urine albumin-to-creatinine ratio* mg/mg 2.0 ± 0.5 5.1 ± 0.8 0.02 ± 0.00 0.05 ± 0.02
Parameters marked with “*” show a significant difference (p < 0.05) comparing WT and P2Y2-R KO SNX groups (mean ± SEM).
FIGURE 4 | During the observation period, UACR significantly
increased in the SNX groups compared to the sham surgery groups
(day 28 and 56, ∗p < 0.05). In addition, UACR was significantly higher in
P2Y2-R KO SNX compared to WT SNX (#p < 0.05) (mean ± SEM).
Table 2 | Relative gene expression normalized to 18S expression
levels comparing WT and P2Y2-R KO SNX mice.
Gene Expression SE p-value Result
18S 1.000
TGF-β1 2.191 0.999–4.524 0.047 *(UP)
PAI-1 4.332 1.369–22.287 0.010 *(UP)
NF-κB 2.067 1.096–4.861 0.070
MCP1 4.187 1.102–32.674 0.024 *(UP)
COX1 1.443 0.762–2.621 0.165
PGSE1 1.778 0.858–3.297 0.122
Values higher than 1 indicate higher expression in P2Y2-R KO mice. Data analysis
was performed using REST 2008 V2.0.7 software.
*p < 0.05.
P2Y RECEPTOR EXPRESSION AND PROLIFERATION ASSAY IN HUMAN
GLOMERULAR EPITHELIAL CELLS
To illustrate the proliferative effect explaining the observed hyper-
trophy in the WT mice with functional P2Y2 receptor after SNX,
we assessed P2Y-receptor status in glomerular epithelial cells and
the measured insertion of [3H]-thymidine upon ATP stimulation
FIGURE 5 | Gene expression ratio of target genes indicating tissue
damage and inflammation in WT SNX vs. P2Y2-R KO SNX mice
assessed by qPCR: positive values indicate fold-change in P2Y2-R KO
SNX over WT SNX expression levels. TGF-β1, PAI-1 and MCP1 showed a
significantly higher expression in P2Y2-R KO SNX than WT SNX mice
(∗p < 0.05). (Boxes represent the interquartile range. Whiskers represent
the minimum and maximum observations. Analysis was performed with
REST 2008V2.0.7 software).
in order to estimate DNA synthesis which is an indicator of
cell proliferation. RT-PCR with specific primers for P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11 receptors confimed the expression of these
receptor subtypes in WT human glomerular epithelial cells (data
not shown).
Human glomerular epithelial cells were stimulated with
increasing doses of ATP (1–100μM) in an ex vivo assay.
Compared to non-stimulated controls, ATP induced a significant,
dose dependent increase in DNA synthesis up to 180.1 ± 20.5%
(Figure 6B).
DISCUSSION
Chronic kidney disease is a major health burden and has a major
impact on cardiovascular morbidity and mortality (Matsushita
et al., 2010). Progression of kidney disease is vastly dependent
on two factors: inflammatory response and fibrotic remodeling.
The progression of chronic kidney disease is linked to a pro-
gressive scarring of glomeruli and subsequent development of
tubulointerstitial fibrosis (Ma and Fogo, 2003). This is accom-
panied by albuminuria, an independent predictor for cardiovas-
cular events (Matsushita et al., 2010). Diseased kidneys activate
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B
FIGURE 6 | (A) Remnant kidney weight in SNX groups at day 0 and day 56
(∗p < 0.05 compared to day 0; ###p < 0.001 WT SNX vs. P2Y2-R KO SNX).
(B) [3H]-thymidine insertion in WT human glomerular epithelial cells in
dependence of ATP stimulation (0–100μM) (∗p < 0.05 compared to
0μM ATP).
afferent sensory nerves, which project to the sympathetic nuclei
in the central nervous system. This leads to increased sympa-
thetic activity in organs like the heart, blood vessels but also
kidneys (Rump et al., 2000). In chronic kidney disease, sympa-
thetic overactivity, mechanical stress and inflammatory responses
from various cell types within the kidney induce the release
of extracellular ATP (Brecht et al., 1976; Gerasimovskaya et al.,
2002; Oberg et al., 2004; Kotanko, 2006; Suliman and Stenvinkel,
2008; Masuo et al., 2010). This excess of extracellular ATP likely
leads to activation of various P2 receptor subtypes. However,
it remains unclear whether activation of P2 receptors mod-
ulates the outcome in chronic kidney disease. A P2 receptor
subtype, which has been associated with nephron function and
renal cell proliferation, is the P2Y2 receptor (Harada et al., 2000;
Vonend et al., 2003; Pochynyuk et al., 2008). This study elu-
cidates the P2Y2 receptor’s role in a model of chronic kidney
disease.
The decreased survival in P2Y2-R KO mice after SNX is
one of the most striking findings, which indicates a general
role of the P2Y2 receptor in chronic kidney disease. To evalu-
ate the underlying cause of this difference, we assessed blood
pressure, physiological parameters and histology throughout the
study.
Chronic kidney disease is associated with increased blood
pressure due to increased sympathetic activity and activation of
the renin angiotensin system (Mailloux, 2001; Vonend et al., 2008;
U.S. Renal Data System, 2011). It has been shown previously that
mice develop hypertension after SNX (Ma and Fogo, 2003). In
our study, sham surgery and SNX mice showed a similar sys-
tolic blood pressure at baseline. In sham surgery mice, systolic
blood pressure remained stable during the observation period. In
the SNX groups, blood pressure significantly increased over time.
Interestingly, P2Y2-R KO mice developed a significantly higher
blood pressure compared to WT SNX mice.
P2Y2 receptor activation is a crucial element in a variety of
physiological mechanisms that influence blood pressure. These
mechanisms include endothelium function and vasoconstric-
tion in the vasculature, modulation of inflammatory response of
immune cells and modulation of epithelial function. The P2Y2
receptor is expressed along the nephron and plays an impor-
tant role in tubule epithelial function (Unwin et al., 2003). In
the distal nephron, Ponchynyuk et al. showed that P2Y2 recep-
tor activation decreases the open probability of the epithelial
sodium channel (ENaC) leading to increased natriuresis and
water excretion (Pochynyuk et al., 2008, 2010). Rieg et al. then
demonstrated that P2Y2 receptor activation causes an immedi-
ate drop in blood pressure and increases the fractional sodium
excretion. In P2Y2-R KO mice, sodium excretion was reduced
compared to WT mice. This also caused a decrease in free
water excretion. Rieg et al. could not observe any difference
in glomerular filtration rate at baseline or upon stimulation of
P2Y2 receptor, nor could they detect any difference in mean
blood pressure at baseline comparing WT and KO mice (Rieg
et al., 2011). In this study, Rieg et al. used P2Y2-R KO mice
on a SV129 background, using mice from the same source as
mice used in our study. The results are consistent with our
findings, which show no significant difference in systolic blood
pressure of P2Y2-R KO compared to WT mice at baseline.
However, in an earlier study, using mice on a C57Bl/6 back-
ground, significantly higher baseline systolic blood pressure in
these KO mice was observed (Rieg et al., 2007). Rieg et al.
assumed that the genetic background might explain this differ-
ence. Even though basal systolic blood pressure did not differ in
our study, in P2Y2-R KO SNX mice, systolic blood pressure was
significantly higher at the end of the observational period com-
pared to WT SNX mice. This might be explained by the lack of
P2Y2 receptor activation and its effects on natriuresis and water
excretion.
Another factor that might contribute to the elevated blood
pressure in P2Y2-R KO mice is the impact of endothelial
vasodilatation upon P2Y2 receptor activation. This response
is driven by endothelium-derived hyperpolarizing factor and
nitric oxide production (Marrelli, 2001; Buvinic et al., 2002;
da Silva et al., 2009; Raqeeb et al., 2011). Impaired endothelial
vasorelaxation is a hallmark of endothelial dysfunction which
occurs in the setting of chronic kidney disease. Therefore, it
is feasible that P2Y2 receptor deficiency in chronic kidney dis-
ease contributes to the impaired endothelial function result-
ing in elevated systolic blood pressure as observed in our
study.
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In our study, progression of kidney disease after SNXwasmore
pronounced in P2Y2-R KO mice than in WT controls. Creatinine
clearance was significantly reduced, and both albuminuria and
serum urea were significantly higher in P2Y2-R KO mice after
SNX. Since increased blood pressure accelerates the decline of
kidney function and increases proteinuria, the difference in sys-
tolic blood pressure is likely to be one of the contributing factors
for the observed outcome (Young et al., 2002; Matsushita et al.,
2010).
However, if increased systolic blood pressure was the sole cause
for worse outcome in the P2Y2 receptor KO group, a marked dif-
ference in glomerulosclerosis should be present in these mice.
Histological assessment of the kidneys could not reveal any dif-
ference in glomerulosclerosis (data not shown). This finding
suggests that mechanisms other than increased blood pressure
contribute to the marked difference in renal function between
P2Y2-R KO and WT SNX mice.
As stated above, progression of kidney disease is also depen-
dent on the inflammatory response to kidney injury. It has been
shown that P2Y2 receptors have a direct impact on inflammation
and proliferation.
In order to delineate mechanisms other than increased systolic
blood pressure, mRNA expression was analyzed at day 56 after
SNX. Markers indicating increased maladaptive changes were sig-
nificantly increased in P2Y2-R KO SNX mice. TGF-β1 and PAI-1
showed a significant increase at day 56 after SNX in the P2Y2-R
KO group (Figure 5). TGF-β1 not only reflects increased tissue
damage but can act as a strong inducer of inflammation (Lan and
Chung, 2012).
The progressive decline in kidney function and the differences
between WT and KO SNX mice in our study, might be asso-
ciated with modulation of the inflammatory response (Suliman
and Stenvinkel, 2008). P2Y2 receptors are among the P2 recep-
tors that show markedly increased expression in macrophages
after induction of inflammatory response indicating a poten-
tial role of the P2Y2 receptor in the regulation of inflam-
mation (Luttikhuizen et al., 2004). Others showed that P2Y2
receptor activation increases the expression of cyclooxygenase-
1/2 and release of prostaglandin E2 (PGE2) which inhibits
the release of pro-inflammatory cytokines from macrophages
and T-lymphocytes (Welch et al., 2003; Degagne et al., 2009;
Kalinski, 2012). Furthermore, administration of the P2Y2 recep-
tor agonist UTP greatly reduced the infiltration of neutrophils
after myocardial infarction, an effect which was abolished in
P2Y2-R KO mice (Cohen et al., 2011). Therefore, activation
of P2Y2 receptors in an inflammatory setup can limit the
extent of inflammatory response. Since a sustained inflamma-
tion contributes to the progression of chronic kidney disease,
deficiency of P2Y2 receptors might be detrimental for kidney
function.
In order to assess effects on inflammation, we analyzed mRNA
expression of NfκB, MCP1, PGSE1, and COX1 in SNX kidney
cortex samples. NfκB, PGSE1, and COX1 showed a statistically
non-significant tendency toward higher expression in P2Y2-R
KO SNX mice. It is well-known that in this model, differences
in mRNA levels in late observational periods tend to be subtle,
since a steady state with slow progression of kidney disease has
been established (Rumberger et al., 2007). This might partially
explain the non-significant differences in some of the inflam-
matory markers in qPCR assessment. Interestingly, at day 56,
MCP1 expression was higher in P2Y2-R KO SNX compared
to WT SNX mice, which indicates an increased inflammatory
response in the KO SNX group. Since sustained inflamma-
tion accelerates the progression of chronic kidney disease, this
might partially explain the worse outcome in P2X2-R KO mice
after SNX.
In addition to modulating inflammation, P2Y receptors are
also involved in the regulation of proliferation and hypertro-
phy. Vonend et al. showed that P2Y receptor activation promotes
proliferation of human mesangial cells (Vonend et al., 2003).
In our study, WT SNX mice showed a significant increase in
remnant kidney weight whereas remnant kidneys in P2Y2-R KO
SNX mice failed to show a significant increase in renal mass.
These adaptive processes are sustained by a proliferation of dif-
ferent renal cell types, leading to an increase in glomerular size
and increase in tubular tissue, which can partially compensate
for the reduced GFR and therefore counteract the decline in
kidney function (Waldherr and Gretz, 1988; Hoy et al., 2003;
Alperovich et al., 2004). In the absence of the P2Y2 receptor,
these adaptive mechanisms seem to be abolished and could par-
tially explain the lower creatinine clearance in the KO SNX
mice.
The balance between proliferation and apoptosis depends
upon the concentration of extracellular ATP and on the subtype
of stimulated P2-receptors (Harada et al., 2000). Extracellular
ATP leads to a dose-dependent proliferation of mesangial cells in
a manner that is P2Y2 receptor dependent (Harada et al., 2000).
In our study, deficiency of P2Y2 receptor abolished most of the
remnant kidney hypertrophy following SNX. In addition, albu-
minuria was significantly higher in the P2Y2-R KO group. To
illustrate the proliferative effect explaining the observed hyper-
trophy in the WT mice with functional P2Y2 receptor after SNX,
we observed a dose dependent increase in cell proliferation by
ATP stimulation in glomerular epithelial cells. These cells are
essential for the structure of the glomerular filtration barrier and
their integrity is important to prevent albuminuria. The lack of
compensatory hypertrophy might contribute to the worse out-
come after subtotal nephrectomy in the P2Y2 receptor deficient
group.
In summary, P2Y2 receptor deficiency is detrimental in
chronic kidney disease. This is most likely caused by increased
elevation of systolic blood pressure. The P2Y2 receptor also mod-
ulates inflammation and proliferation which may also contribute
to the progression of chronic kidney disease in our model. We
conclude that the P2Y2 receptor is crucial for blood pressure reg-
ulation and response to renal injury after induction of chronic
kidney disease. Therefore, the P2Y2 receptor stimulation might
be a potential therapeutic target.
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